Let me be clear upfront: this is not an anti-Ozempic post. The evidence for GLP-1 receptor agonists in managing obesity, type 2 diabetes, and related metabolic conditions is genuinely strong, and I won't pretend otherwise. For some people, these drugs are a clinically appropriate tool. But a conversation about pharmaceutical GLP-1 that doesn't include GLP-1 as a naturally occurring hormone — one you already produce, one that responds to diet and lifestyle inputs, and one whose dysfunction often precedes the symptoms that lead people to consider medication — is a very incomplete conversation.
This post is part one of two. Here we'll cover what GLP-1 is, how it works, what impairs it, and how to optimise it naturally. Part two will deal with the exercise-appetite paradox — why exercise often increases hunger during weight loss, why the biology behind that is not a failure of willpower, and why the framing matters clinically.
GLP-1: The Hormone Your Gut Is Already Making
Glucagon-Like Peptide-1 (GLP-1) is a hormone secreted primarily by L-cells in the distal small intestine and colon in response to food entering the gut. It was first characterised in the 1980s and has since been identified as one of the most important modulators of metabolic function in the body. Ozempic, Wegovy, Mounjaro — these are all synthetic analogues or dual agonists designed to mimic and extend the action of GLP-1 (and in the case of tirzepatide, also GIP, another incretin hormone).
The pharmaceutical versions work partly by having a much longer half-life than endogenous GLP-1, which is broken down rapidly by the enzyme DPP-4 within minutes of release. But the mechanisms they activate are the same ones your body uses naturally. Understanding those mechanisms explains both why the drugs work and what you can do to enhance your own GLP-1 response.
What GLP-1 Actually Does
| Action | Mechanism | Clinical Relevance |
|---|---|---|
| Stimulates insulin secretion | Acts on pancreatic beta cells in a glucose-dependent manner | Reduces post-meal glucose spike without risk of hypoglycaemia |
| Suppresses glucagon | Acts on pancreatic alpha cells | Reduces fasting glucose and hepatic glucose output |
| Slows gastric emptying | Acts on vagal afferents and enteric nervous system | Extends satiety, reduces post-meal glucose rise |
| Reduces appetite | Acts on hypothalamic appetite centres via vagus nerve | Decreases caloric intake, increases sense of fullness |
| Protects beta cells | Anti-apoptotic effects on pancreatic beta cells | Potentially disease-modifying in type 2 diabetes |
| Cardiovascular protection | Reduces inflammation, improves endothelial function | Confirmed CV risk reduction in outcome trials |
The appetite suppression mechanism is particularly important to understand. GLP-1 does not simply tell you "you've had enough food" at a conscious level. It acts centrally — on the hypothalamus and brainstem — to genuinely shift the set point around which your hunger and satiety signals operate. This is why people on GLP-1 agonists often describe not thinking about food, not being hungry, not feeling the compulsive pull towards calorie-dense foods that characterises eating in a state of metabolic dysfunction. The drug is not providing willpower. It is correcting a hormonal signal that was impaired.
"If GLP-1 is already doing all of this in your body, the question isn't just 'should I take the drug?' — it's 'why is my own GLP-1 response inadequate, and what can I do about it?'"
Why Your GLP-1 Response May Be Blunted
Research has consistently shown that individuals with obesity, insulin resistance, and type 2 diabetes tend to have impaired post-meal GLP-1 responses compared to metabolically healthy individuals. This is not simply a consequence of obesity — there is evidence it contributes to it. Impaired GLP-1 release means less satiety signalling, faster gastric emptying, higher post-meal glucose, and less appetite regulation. The feedback loop that should slow eating and signal fullness is running below capacity.
The drivers of impaired GLP-1 secretion include:
Gut microbiome composition. L-cells, which secrete GLP-1, respond to signals from the gut microbiome. Butyrate — produced by fermentation of dietary fibre by specific bacterial species — is a direct stimulant of GLP-1 secretion from L-cells. A dysbiotic gut with low levels of butyrate-producing bacteria (Faecalibacterium prausnitzii, Roseburia intestinalis, Akkermansia muciniphila are key species here) produces less GLP-1 in response to the same dietary inputs.
Food processing and texture. Ultra-processed foods are designed to clear the stomach rapidly and bypass the satiety mechanisms that intact whole foods trigger. GLP-1 secretion is stimulated by the physical presence of food components — particularly fibre, protein, and fat — in the small intestine. A meal that passes through quickly triggers a smaller, shorter GLP-1 response than one that takes longer to clear.
Chronic inflammation. Systemic low-grade inflammation — common in metabolic syndrome, gut dysbiosis, and high-stress states — impairs the sensitivity of GLP-1 receptors and reduces L-cell responsiveness. This is a significant contributor to the progressive blunting of satiety signals that many people experience as their metabolic health deteriorates.
Sleep deprivation. As covered in the Non-Negotiables post, poor sleep drives ghrelin up and leptin down. It also appears to impair GLP-1 secretion. A 2016 study in Obesity found that partial sleep deprivation significantly reduced post-meal GLP-1 levels in overweight adults, alongside increased caloric intake and reduced satiety ratings — independent of caloric content of the meals consumed.
Akkermansia muciniphila and GLP-1
One of the most researched gut bacteria in the context of metabolic health, Akkermansia muciniphila colonises the mucus layer of the gut and has been shown to enhance gut barrier integrity, reduce endotoxin translocation (leaky gut), and — critically — stimulate GLP-1 secretion from L-cells.
A 2019 pilot randomised controlled trial published in Nature Medicine by Depommier et al. found that pasteurised Akkermansia supplementation in metabolically compromised adults improved insulin sensitivity, reduced insulin levels, and was associated with favourable changes in gut permeability markers — with a postulated GLP-1 mechanism as one of the contributing pathways.
Dietary inputs that increase Akkermansia include: cranberry polyphenols, pomegranate extract, green tea catechins, and resistant starch. It is one of the reasons a diverse, plant-rich diet with adequate polyphenol exposure genuinely matters for metabolic health — not just in a vague "healthy eating" sense, but in a specific hormonal mechanism sense.
Gastric Emptying Rate: The Underrated Satiety Variable
One of the most important and least discussed determinants of satiety is how long your food spends in your stomach. GLP-1 slows gastric emptying — this is part of its satiety mechanism. But the food you eat also directly determines how long it spends in the stomach before that GLP-1 signal is even triggered.
Solid food takes substantially longer to clear the stomach than liquids. Food with intact cell walls — whole grains, legumes, intact vegetables — requires more time and digestive work than the same food processed into a smooth paste. A smoothie and a meal of whole fruit and vegetables with the same caloric content will generate different hormonal responses, different satiety signals, and different effects on post-meal blood glucose — even if the macro content is identical on paper.
This is clinically relevant for several populations:
Protein shakes and meal replacement drinks: The protein content may be adequate, but the physical form bypasses much of the mechanical satiety signalling that comes from chewing intact food, distending the stomach with solid material, and triggering the cephalic phase digestive response. For someone trying to manage weight and improve satiety, liquid meals are a poor substitute for the equivalent food in whole form — unless there is a clinical reason (swallowing difficulties, post-surgical recovery, active gut inflammation) for using them.
Smoothies vs whole fruit: A smoothie made with three pieces of fruit passes through the stomach in 20–30 minutes. Eating three pieces of whole fruit, chewing thoroughly, and consuming them over a similar time period will produce a slower gastric emptying rate, a more sustained GLP-1 response, and a smaller post-meal glucose spike. The fibre matrix matters. The physical structure matters.
"The question isn't only what you eat. It's what form it takes and how long it spends in contact with the gut wall that triggers GLP-1."
The Scale Weight Problem: Glycogen, Water, and the Biology of Weight Loss
Anyone who has started a dietary change programme and stepped on the scales after the first week knows the phenomenon: a dramatic drop — three, four, five kilograms — followed by a plateau or slight rebound that feels deeply discouraging. Understanding the biology of this prevents unnecessary distress and is relevant to how we discuss weight loss expectations with clients.
Glycogen — the stored form of glucose in the liver and skeletal muscle — holds approximately three grams of water per gram of glycogen. When you reduce carbohydrate intake or enter a caloric deficit, the first fuel mobilised is glycogen. As glycogen is depleted, that bound water is released. This is why the first week of any dietary change protocol produces rapid scale weight loss — you are losing glycogen-bound water, not primarily adipose tissue.
Conversely, when you increase carbohydrate intake, resume normal eating after a period of restriction, or start a new exercise programme (which drives glycogen synthesis), scale weight increases — because glycogen is being stored and bringing water with it. This is not fat gain. But without understanding the biology, it reads exactly like it.
Glycogen Repletion and the Post-Exercise Weight Paradox
Someone starting a new exercise programme may see no change — or even a slight increase — in scale weight in the first four to eight weeks, despite improved body composition (increased muscle, reduced fat). The glycogen loading effect in newly stressed muscle, combined with the inflammatory fluid response to novel training stimuli, can mask genuine fat loss. Body composition measurement (DEXA scan, hydrostatic weighing, or even consistent waist circumference measurement) is a far more useful metric than scale weight for anyone doing meaningful exercise alongside dietary change.
This matters clinically because people who are not warned about it quit their exercise programme when the scale doesn't move or goes up, concluding that "exercise doesn't work for weight loss." The exercise is working. The scale measurement is simply not capturing what's actually happening.
How to Optimise Your Endogenous GLP-1 Response
Putting it all together, here is what the evidence supports for enhancing your own GLP-1 secretion and sensitivity before pharmaceutical intervention is on the table:
Evidence-Based GLP-1 Optimisation Protocol
- Prioritise intact whole foods over processed equivalents. Every meal. The physical matrix of whole food — fibre, cell wall structure, intact protein — drives GLP-1 secretion. Ultra-processed foods, by design, minimise this. Choose the apple over the applesauce. The lentils over the lentil soup puree. The chicken breast over the processed protein product.
- Eat substantial protein at each meal. Protein is the most potent dietary stimulant of GLP-1 secretion. A minimum of 25–40g of high-quality protein per meal is a reasonable target. Leucine-rich sources (whey, eggs, meat, fish) appear particularly effective. This is also the most protective macronutrient for lean mass preservation during weight loss.
- Include fermentable fibre daily. Legumes, oats, cooked and cooled rice (resistant starch), green banana, leeks, asparagus, chicory — these feed butyrate-producing bacteria and enhance L-cell GLP-1 secretion. Thirty grams of total dietary fibre per day is the minimum evidence-based target for gut health; most UK adults consume under 20g.
- Add polyphenol-rich foods. Berries, pomegranate, green tea, dark chocolate (85%+), extra virgin olive oil — these enhance Akkermansia and other beneficial species associated with better GLP-1 response. They are also anti-inflammatory, which reduces receptor blunting.
- Eliminate liquid calories where possible. Smoothies, fruit juices, sugary drinks, and most protein shakes bypass gastric emptying rate as a satiety mechanism. For someone trying to improve satiety and GLP-1 response, this matters more than the calorie counting aspect.
- Prioritise sleep. Eight hours. Consistent timing. The GLP-1 suppression effect of sleep deprivation is measurable and clinically significant.
- Address gut dysbiosis. If your gut microbiome is significantly disrupted — and a GI-MAP test will tell you if it is — no dietary intervention will optimise your GLP-1 response fully until the underlying microbial composition is addressed. The L-cells need the right microbial signals to perform.
A Note on the Medication Conversation
If you've read this post and are still considering or currently using GLP-1 agonists, the framework above doesn't conflict with that. The dietary and lifestyle strategies are additive to pharmaceutical GLP-1 support, not alternatives. What I would say is this:
If you are considering GLP-1 medication because you are struggling with appetite, weight, and metabolic function despite genuine lifestyle effort — that is a valid clinical conversation to have with a qualified physician. The drugs work. The evidence is robust.
But if you are considering GLP-1 medication without having seriously addressed your gut microbiome, your dietary fibre and protein intake, your sleep, and your processed food consumption — you are potentially medicalising a problem that has significant biological drivers that have not yet been investigated. That's not to judge anyone's decision. It's to ensure the conversation is complete.
Test, don't guess. If satiety and appetite are major issues for you, a functional gut microbiome assessment will tell you whether your GLP-1 machinery is working with the microbial inputs it needs — and give you a targeted place to start.
Part 2: Exercise, Appetite & the Weight Loss Paradox
Why does exercise make you hungrier during weight loss — and what does that mean for your programme design? Part two covers the exercise-appetite compensation effect, why it's not a failure, and how to work with it rather than against it.
Read Part 2 →Stephen Duncan FDN-P MSc. References: Holst JJ (2007), Physiological Reviews — comprehensive GLP-1 review; Depommier C et al. (2019), Nature Medicine — Akkermansia and metabolic health; Brouns F et al. (2012), Nutrition Research Reviews — gastric emptying and satiety; Hogenkamp PS et al. (2013) / Schmid SM et al. (2008), various — sleep deprivation and appetite hormones; Sonnenburg J & Bäckhed F (2016), Nature — gut microbiome and metabolic disease; Flint A et al. (2006), International Journal of Obesity — protein and GLP-1 secretion; SUSTAIN and LEADER trial data — cardiovascular outcomes with GLP-1 agonists.